文献速递药物相互作用治疗药物监测与药物基因组学药物不良反应与药物警戒

中国儿童ALL患者长春新碱诱导周围神经病变的药动学、药效学与药物基因组学研究

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine-Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients.
PubMed 文献 · Clin Pharmacol Ther · 2024-10-04

该研究纳入79例接受长春新碱(VCR)治疗的中国儿童急性淋巴细胞白血病(ALL)患者,构建群体药动学与PK/PD模型,考察清除途径、药物相互作用(DDI)及遗传特征对VCR诱导周围神经病变(VIPN)的影响。结果显示,ABCB1-rs1128503基因型与泊沙康唑(POS)合用显著改善模型拟合,VIPN与VCR暴露显著相关,POS合用使VCR暴露增加0.4倍并提高VIPN风险。

要点

  • 泊沙康唑合用使VCR暴露增加0.4倍,VIPN发生概率通常超过0.7。
  • ABCB1-rs1128503基因型与泊沙康唑是影响VCR群体药动学的显著因素。
  • VIPN与VCR暴露显著相关,提示临床可能需要开展VCR治疗药物监测。

核心结论

  • 泊沙康唑合用使VCR暴露增加0.4倍并提高VIPN风险,发生概率通常超过0.7。
  • 临床实践中可能需要开展VCR治疗药物监测以支持剂量调整和个体化治疗。

研究设计与样本

  • 研究纳入79例接受ALL治疗的儿童患者,采用新方法测定VCR及其代谢物M1。
  • 记录VIPN发生情况,对相关PK和PD基因进行DNA测序。
  • 构建PopPK和PK/PD模型,并进行药物基因组学和DDI分析。

主要发现

  • 异速增长、ABCB1-rs1128503基因型和泊沙康唑显著改善PopPK模型拟合。
  • VIPN与VCR暴露显著相关。
  • 合用泊沙康唑使VIPN效应曲线左移,相同暴露水平下VIPN风险增加。
  • CYP3A5(rs776746)、CYP3A4(rs2242480)、CEP72(rs924607)及多种ABCB1变异对VIPN无显著影响。
  • 合用氟康唑或达沙替尼对VIPN无显著影响。

临床怎么用

  • 合用泊沙康唑时需警惕VCR暴露增加及VIPN风险升高。
  • 可考虑对VCR开展治疗药物监测以指导剂量调整和个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vincristine (VCR) can cause vincristine-induced peripheral neuropathy (VIPN) during the treatment of acute lymphoblastic leukemia (ALL) and the mechanisms are complicated. The aim of this study was to investigate the influencing factors on the population pharmacokinetics (PopPK) and pharmacodynamics (PD) related to VIPN, including clearance routes, drug-drug interactions (DDI), and genetic characteristics. Pediatric patients being treated for ALL were recruited to PK study where VCR and its metabolite (M1) were measured using a novel assay. The incidence of VIPN was also recorded. DNA sequencing of relevant PK and PD genes was performed. PopPK and PK/PD models were developed, pharmacogenetic and DDI analyses were conducted. In total, 79 children were recruited. The results showed that allometric scaling, ABCB1-rs1128503 genotype, and posaconazole (POS) significantly improved the PopPK model fit. VIPN was significantly correlated with the exposure of VCR. Co-administration with POS shifted the effect curve for VIPN to the left, indicating increased VIPN risk at the same exposure levels. No significant effects on VIPN were observed for CYP3A5 (rs776746), CYP3A4 (rs2242480), CEP72 (rs924607), or various ABCB1 variants (rs1128503, rs2032582, rs1045642, rs4728709, rs4148737, and rs10276036), nor with the co-administration of fluconazole or dasatinib. In summary, co-administration of POS increased VCR exposure by 0.4-fold and raised the risk of VIPN, with an occurrence probability generally exceeding 0.7. Therapeutic drug monitoring of VCR in clinical practice may be necessary to enable appropriate dose adjustments and individualized treatment.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Hu W, Chen C, et al. Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine-Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients. Clin Pharmacol Ther. 2024. PMID: 39367622. doi:10.1002/cpt.3462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。